Delmas PD, Bjarnason NH, Mitlak BH.
et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations,
and uterine endometrium in postmenopausal women. N Engl J Med.1997;337:1641-1647.
Temple RJ.A regulatory authority's opinion about surrogate endpoints.In: Nimmo WS, Tucker GT, eds. Clinical Measurement
in Drug Evaluation. New York, NY: John Wiley & Sons Inc; 1995:57.
Hammer SM, Katzenstein DA, Hughes MD.
et al. A trial comparing nucleoside monotherapy with combination therapy in
HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med.1996;335:1081-1090.
Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations
of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected
Saravolatz LD, Winslow DL, Collins G.
et al. Zidovudine alone or in combination with didanosine or zalcitabine in
HIV-infected patients with the acquired immunodeficiency syndrome or fewer
than 200 CD4 cells per cubic millimeter. N Engl J Med.1996;335:1099-1106.
Hammer SM, Squires KE, Hughes MD.
et al. A controlled trial of two nucleoside analogues plus indinavir in persons
with human immunodeficiency virus infection and CD4 cell counts of 200 per
cubic millimeter or less. N Engl J Med.1997;337:725-733.
Niebauer J, Coats AJ.Treating chronic heart failure: time to take stock. Lancet.1997;349:966-967.
Massie BM, Berk MR, Brozena SC.
et al. Can further benefit be achieved by adding flosequinan to patients with
congestive heart failure who remain symptomatic on diuretic, digoxin, and
an angiotensin converting enzyme inhibitor? results of the flosequinan-ACE
inhibitor trial (FACET). Circulation.1993;88:492-501.
How to read clinical journals, IV: to determine etiology or causation. CMAJ.1981;124:985-990.
Oxman AD, Sackett DL, Guyatt GH.Users' guides to the medical literature, I: how to get started. JAMA.1993;270:2093-2095.
Guyatt G, Walter S, Shannon H, Cook D, Jaeschke R, Heddle N.Basic statistics for clinicians, IV: correlation and regression. CMAJ.1995;152:497-504.
Guyatt GH, Thompson PJ, Berman LB.
et al. How should we measure function in patients with chronic heart and lung
disease? J Chronic Dis.1985;38:517-524.
Mahler DA, Weinberg DH, Wells CK, Feinstein AR.The measurement of dyspnea: contents, interobserver agreement, and
physiologic correlates of two new clinical indexes. Chest.1984;85:751-758.
Verschuren WM, Jacobs DR, Bloemberg BP.
et al. Serum total cholesterol and long-term coronary heart disease mortality
in different cultures. JAMA.1995;274:131-136.
Mellors JW, Rinaldo Jr CR, Gupta P.
et al. Prognosis in HIV-1 infection predicted by the quantity of virus in
Mellors JW, Kingsley LA, Rinaldo CR.
et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med.1995;122:573-579.
Ruiz L, Romeu J, Clotet B.
et al. Quantitative HIV-1 RNA as a marker of clinical stability and survival
in a cohort of 302 patients with a mean CD4 cell count of 300 × 10(6)/1. AIDS.1996;10:F39-F44.
O'Brien TR, Blattner WA, Waters D.
et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter
Hemophilia Cohort Study. JAMA.1996;276:105-110.
Yerly S, Perneger TV, Hirschel B.
et al. A critical assessment of the prognostic value of HIV-1 RNA levels and
CD4+ cell counts in HIV-infected patients. Arch Intern Med.1998;158:247-252.
Ho DD.Viral counts in HIV infection. Science.1996;272:1124-1125.
Cummings SR, Nevitt MC, Browner WS.
et al. Risk factors for hip fracture in white women. N Engl J Med.1995;332:767-773.
Marshall D, Johnell O, Wedel H.Meta-analysis of how well measures of bone mineral density predict
occurrence of osteoporotic fractures. BMJ.1996;312:1254-1259.
Huang C, Ross PD, Wasnich RD.Short-term and long-term fracture prediction by bone mass measurements. J Bone Miner Res.1998;13:107-113.
Bigger Jr JT, Fleiss JL, Kleiger R.
et al. The relationships among ventricular arrhythmias, left ventricular dysfunction,
and mortality in the 2 years after myocardial infarction. Circulation.1984;69:250-258.
McAlister FA, Teo KK.Antiarrhythmic therapies for the prevention of sudden cardiac death. Drugs.1997;54:235-252.
Echt DS, Liebson PR, Mitchell LB.
et al. and the Cardiac Arrhythmia Suppression Trial. Mortality and morbidity in patients receiving encainide, flecainide,
or placebo. N Engl J Med.1991;324:781-788.
Moore TJ.Deadly Medicine.New York, NY: Simon & Schuster; 1995.
Drexler H, Banhardt U, Meinertz T.
et al. Contrasting peripheral short-term and long-term effects of converting
enzyme inhibition in patients with congestive heart failure: a double-blind,
placebo-controlled trial. Circulation.1989;79:491-502.
Lewis GR.Comparison of lisinopril versus placebo for congestive heart failure. Am J Cardiol.1989;63:12D-16D.
Giles TD, Fisher MB, Rush JE.Lisinopril and captopril in the treatment of heart failure in older
patients. Am J Med.1988;85:44-47.
Riegger GA.Effects of quinapril on exercise tolerance in patients with mild to
moderate heart failure. Eur Heart J.1991;12:705-711.
Garg R, Yusuf S.Overview of randomized trials of angiotensin-converting enzyme inhibitors
on mortality and morbidity in patients with heart failure. JAMA.1995;273:1450-1456.
Di Bianco R, Shabetai R, Kostuk W.
et al. A comparison of oral milrinone, digoxin, and their combination in the
treatment of patients with chronic heart failure. N Engl J Med.1989;320:677-683.
Sueta CA, Gheorghiade M, Adams KF.
et al. and the Epoprostenol Multicenter Research Group. Safety and efficacy of epoprostenol in patients with severe congestive
heart failure. Am J Cardiol.1995;75:34A-43A.
Packer M, Carver JR, Rodeheffer RJ.
et al. for the Promise Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med.1991;325:1468-1475.
Califf RM, Adams KF, McKenna WJ.
et al. A randomized controlled trial of epoprostenol therapy for severe congestive
heart failure. Am Heart J.1997;134:44-54.
Yee KM, Struthers AD.Can drug effects on mortality in heart failure be predicted by any
surrogate measure? Eur Heart J.1997;18:1860-1864.
Hampton JR, van Veldhuisen DJ, Kleber FX.
et al. Randomised study of effect of ibopamine on survival in patients with
advanced severe heart failure. Lancet.1997;349:971-977.
Cameron DW, Heath-Chiozzi M, Danner S.
et al. and the Advanced HIV Disease Ritonavir Study Group. Randomised placebo-controlled trial of ritonavir in advanced HIV-1
Watts NB, Harris ST, Genant HK.
et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med.1990;323:73-79.
Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH.Effect of intermittent cyclical etidronate therapy on bone mass and
fracture rate in women with postmenopausal osteoporosis. N Engl J Med.1990;322:1265-1271.
Liberman UA, Weiss SR, Broll J.
et al. and the Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence
of fractures in postmenopausal osteoporosis. N Engl J Med.1995;333:1437-1443.
Riggs BL, Hodgson SF, O'Fallon WM.
et al. Effect of fluoride treatment on the fracture rate in postmenopausal
women with osteoporosis. N Engl J Med.1990;322:802-809.
Meunier PJ, Sebert J-L, Reginster J-Y.
et al. Fluoride salts are no better at preventing new vertebral fractures
than calcium-vitamin D in postmenopausal osteoporosis. Osteoporos Int.1998;8:4-12.
Dawson-Hughes B, Harris SS, Krall EA, Dallal GE.Effect of calcium and vitamin D supplementation on bone density in
men and women 65 years of age and older. N Engl J Med.1977;337:670-676.
McAlister FA, Straus S, Sackett DL.Randomized clinical trials of antihypertensive drugs: all that glitters
is not gold. CMAJ.1998;159:488-490.
Staessen JA, Fagard R, Thijs L.
et al. Randomised double-blind comparison of placebo and active treatment
for older patients with isolated systolic hypertension. Lancet.1997;350:757-764.
Psaty BM, Siscovick DS, Weiss NS.
et al. Hypertension and outcomes research: from clinical trials to clinical
epidemiology. Am J Hypertens.1996;9:178-183.
Borhani NO, Mercuri M, Borhani PA.
et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis
study (MIDAS): a randomized controlled trial. JAMA.1996;276:785-791.
Tatti P, Pahor M, Byington RP.
et al. Outcome results of the fosinopril versus amlodipine cardiovascular
events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care.1998;21:597-603.
Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW.The effect of nisoldipine as compared with enalapril on cardiovascular
outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med.1998;338:645-652.
McAlister FA, Laupacis A, Wells GA, Sackett DL.for the Evidence-Based Medicine Working Group. Users' guide to the medical literature, XIX: applying clinical trial
results part B: guidelines for determining whether a drug is exerting (more
than) a class effect. JAMA.In press.
Bucher HC, Griffith LE, Guyatt GH.Systematic review on risk and benefit of different cholesterol lowering
interventions. Arterioscler Thromb Vasc Biol.1999;19:187-195.
Muldoon MF, Manuck SB, Matthews KA.Lowering cholesterol concentration and mortality. BMJ.1990;301:309-314.
Smith GD, Song F, Sheldon TA.Cholesterol lowering and mortality. BMJ.1993;306:1367-1373.
Prentice RL.Surrogate endpoints in clinical trials. Stat Med.1989;8:431-440.
Fleming TR.Surrogate markers in AIDS and cancer trials. Stat Med.1994;13:1423-1435.
Cooper DA, Gatell JM, Kroon S.
et al. and the European-Australian Collaborative Group. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell
counts greater than 400 per cubic millimeter. N Engl J Med.1993;329:297-303.
Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate
and deferred zidovudine in symptom-free HIV infection. Lancet.1994;343:871-881.
Guyatt GH, Sackett DL, Cook DJ.for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, II: how to use an article
about therapy or prevention A: are the results of the study valid? JAMA.1993;270:2598-2601.
Dans AL, Dans LF, Guyatt GH, Richardson S.for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, XIV: how to decide on the
applicability of clinical trial results to your patient. JAMA.1998;279:545-549.
Ettinger B, Black D, Cummings S.
et al. Raloxifene reduces the risk of incident vertebral fractures: 24 month
interim analyses. Osteoporos Int.1998;8(suppl 3):11.
Clendeneninn N, Quart B, Anderson R, Knowles M, Chang Y.Analysis of long-term virologic data from the viracept (nelfinavir)
511 protocol using 3 HIV-RNA assays.In: Abstracts from the 5th Conference on Retroviruses and Opportunistic
Infections; Chicago, Ill; 1998.
Brun-Vezinet F, Boucher C, Loveday C.
et al. and the Delta Virology Working Group and Coordinating Committee. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive
participants from the Delta trial: the national virology groups. Lancet.1997;350:983-990.
Montaner JS, Reiss P, Cooper D.
et al. A randomized, double-blind trial comparing combinations of nevirapine,
didanosine, and zidovudine for HIV-infected patients: the Netherlands, Canada,
and Australia (INCAS) study. JAMA.1998;279:930-937.
CEASAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride
to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR
Fischl M, Greenberg S, Clumeck N.
et al. Safety and activity of abacavir (1592, ABC) with 3TC/ZDV in antiretroviral
naive subjects.In: Abstracts from the 12th World AIDS Conference: Geneva, Switzerland;
June 28-July 3, 1998.
Katzenstein DA, Hammer SM, Hughes MD.
et al. and the AIDS Clinical Trials Group Study 175 Virology Study Team. The relation of virologic and immunologic markers to clinical outcomes
after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells
per cubic millimeter. N Engl J Med.1996;335:1091-1098.
Collins R, Peto R, MacMahon S.
et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term
reductions in blood pressure; overview of randomised drug trials in their
epidemiological context. Lancet.1990;335:827-838.
MacMahon S, Peto R, Cutler J.
et al. Blood pressure, stroke, and coronary heart disease, part 1: prolonged
differences in blood pressure; prospective observational studies corrected
for the regression dilution bias. Lancet.1990;335:765-774.
Psaty BM, Smith NL, Siscovick DS.
et al. Health outcomes associated with antihypertensive therapies used as
first-line agents: a systematic review and meta-analysis. JAMA.1997;277:739-745.
Heinonen TM, Stein E, Weiss SR.
et al. The lipid-lowering effects of atorvastatin, a new HMG-coA reductase
inhibitor: results of a randomized, double-masked study. Clin Ther.1996;18:853-863.
Bakker-Arkema RG, Davidson MH, Goldstein RJ.
et al. Efficacy and safety of a new HMG-coA reductase inhibitor, atorvastatin,
in patients with hypertriglyceridemia. JAMA.1996;275:128-133.
Law MR, Wald NJ, Thompson SG.By how much and how quickly does reduction in serum cholesterol concentration
lower risk of ischaemic heart disease? BMJ.1994;308:367-372.
Winocour PH, Durrington PN, Bhatagnar D.
et al. The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate
density lipoprotein (IDL), and low density lipoprotein (LDL) composition in
type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia. Atherosclerosis.1992;93:83-94.
Jones IR, Swai A, Taylor R, Miller M, Laker MF, Alberti KG.Lowering of plasma glucose concentrations with bezafibrate in patients
with moderately controlled NIDDM. Diabetes Care.1990;13:855-863.
Jones P, Kafonek S, Laurora I, Hunninghake D.Comparative dose efficacy study of atorvastatin versus simvastatin,
pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia
(the CURVES study). Am J Cardiol.1998;81:582-587.
Downs JR, Clearfield M, Weis S.
et al. Primary prevention of acute coronary events with lovastatin in men
and women with average cholesterol levels. JAMA.1998;279:1615-1622.
Shepherd J, Cobbe SM, Ford I.
et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med.1995;333:1301-1307.
Karpf DB, Shapiro DR, Seeman E.
et al. Prevention of nonvertebral fractures by alendronate: a meta-analysis. JAMA.1997;277:1159-1164.
Black DM, Cummings SR, Karpf DB.
et al. and the Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women
with existing vertebral fractures. Lancet.1996;348:1535-1541.
Cummings SR, Eckert S, Krueger KA.
et al. The effect of raloxifene on risk of breast cancer in postmenopausal
Ettinger B, Black DM, Mitlak BH.
et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis
treated with raloxifene: results from a 3-year randomized trial. JAMA.1999;282:637-645.